Which weight loss injections are actually top rated — and what does that mean?

What makes a weight loss injection 'top rated', trial data or hype?

The phrase 'top rated' gets used loosely online, so it's worth pinning it to something real. In a clinical sense, the two injections that sit at the top of the evidence base are tirzepatide and semaglutide, the active ingredients in Mounjaro and Wegovy respectively. Both have been through large phase-3 trials, both have received NICE technology appraisals, and both are MHRA-licensed specifically for weight management in adults, not borrowed from a diabetes indication.

SURMOUNT-1 (the pivotal tirzepatide trial, which randomised 2,539 adults with obesity) reported average body-weight reductions of around 20–21% at the highest dose over 72 weeks. The STEP 1 trial for semaglutide 2.4mg reported around 15% average reduction over 68 weeks. In the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine, tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks. These are population averages from controlled trial conditions. Individual responses vary, and a prescriber's job is partly to work out which option fits your health picture.

Older agents such as liraglutide (Saxenda) and orlistat capsules also remain licensed in the UK, but their trial results sit well below those of the newer GLP-1 medicines, which is why clinical discussion of 'top rated' options tends to centre on tirzepatide and semaglutide, and our guide to the top weight loss injections explains how each one is evaluated against the evidence. You can read a broader overview of the available weight loss injections if you want to understand the full landscape before any consultation.

Do prescribers actually have a preference between the two?

A question our prescribers hear most weeks is whether one injection is definitively 'better'. The honest answer is that it depends on the individual. Tirzepatide's dual GIP and GLP-1 mechanism does appear to produce larger average weight reductions in trials, and NICE's committee discussion of TA1026 noted that indirect comparisons favour tirzepatide. But clinical suitability involves more than the headline trial figure.

Semaglutide has been in clinical use for longer, which means a larger real-world dataset. The recently approved Wegovy 7.2mg dose, approved by the MHRA in April 2026 as a dedicated single-dose pen, narrows the gap with tirzepatide 15mg in terms of average weight loss, reaching around 20.7% in trials. Whether 7.2mg is appropriate for a given person is a prescriber decision, not a product choice.

Both medicines carry a Black Triangle (▼) designation from the MHRA, meaning additional monitoring is in place. Both require titration, starting at a lower dose and increasing over months, with the prescriber reviewing tolerability at each stage. Neither is suited to someone who wants a quick fix; both are designed to work alongside reduced-calorie eating and increased activity. If you are weighing one against the other, the comparison of the top three weight loss injections breaks down the differences in more detail.

Who qualifies, and are these injections accessible outside the NHS?

UK licensing sets the floor for eligibility: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. A BMI figure alone does not determine suitability; the prescriber assesses your full health history, current medicines, and any contraindications.

On the NHS, access to both medicines is phased and tied to specific criteria set by NICE and NHS England. Waiting lists for specialist weight management services are commonly long. Many people explore a regulated private route as an alternative, particularly those who meet the licensing criteria but not the current NHS cohort thresholds. Private prescribing is legal and regulated; the key is using a pharmacy you can verify on the GPhC register and a service with genuine clinical oversight rather than an automated sign-up form.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the day it is submitted. There is no algorithm making clinical calls. If you are not sure whether you meet the criteria, the options available near you page covers both NHS and private routes by location, and our FAQs address common eligibility questions plainly.

What should you watch for once treatment begins?

Both injections share a broadly similar side-effect profile, led by gastrointestinal symptoms: nausea, loose stools, constipation, indigestion, and reduced appetite. These are most common after starting treatment or stepping up a dose, and for many people they ease within the first couple of weeks. Staying hydrated and eating smaller, lower-fat meals can help the adjustment period.

There are rarer but more serious effects to know about. The MHRA has highlighted acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines. Severe stomach pain that spreads to the back, with or without vomiting, warrants prompt medical attention rather than waiting for your next check-in. Other signs to act on include symptoms of gallbladder problems, signs of an allergic reaction, or significant dehydration from persistent vomiting or diarrhoea.

Injection technique also matters for tolerability. Rotate sites between the abdomen, thigh, and upper arm. Changing the needle with each injection and cleaning the site beforehand reduces the chance of skin reactions, alcohol swabs are a simple addition to your routine. Any questions about missed doses, timing, or what to do if you feel unwell should go to your prescriber or the Patient Information Leaflet for your specific medicine, not a forum. The side-by-side comparison of the best-rated injections covers tolerability differences in more depth for those who want it.

If you would like to talk through which option suits your situation, check your eligibility with our clinical team, the consultation is free, and a prescriber will review your answers the same day.